Overview of Port Delivery System With Ranibizumab
Panelists discuss how the port delivery system (PDS) is a permanent, refillable ocular implant that continuously releases ranibizumab into the vitreous, with the Archway trial demonstrating noninferior vision outcomes compared with monthly ranibizumab injections while reducing treatment burden through 6-month refill intervals.
Video content above is prompted by the following:
- Can you provide an overview of the PDS with ranibizumab approved for treating neovascular age-related macular degeneration?
- How does the device function?
- Could you discuss the key outcomes from the Archway trial for PDS?
Related Content
